Why Is Accuray Incorporated (ARAY) Stock Down -15.28% Today?
Key Takeaways
- ARAY shares fell roughly 15.28% in early trading Tuesday, last around $0.254 versus a prior close of $0.2998.
- The decline follows Monday's roughly 39% surge, which was sparked by a new imaging collaboration with Samsung HME America (Samsung NeuroLogica).
- Today's move reflects profit-taking and a "buy the rumor, sell the news" unwind after a speculative spike on record volume.
- Investors are refocusing on fundamentals: persistent losses, negative margins, a planned reverse stock split, and a prior Nasdaq delisting warning.
- Traders are watching whether the pullback stabilizes and whether trading volume normalizes from Monday's extreme levels.
Opening Summary
Accuray Incorporated (ARAY) is a Madison, Wisconsin-based radiation oncology company that develops, manufactures, and services precision radiation therapy systems, including the CyberKnife robotic radiosurgery platform and the TomoTherapy/Radixact platform. In Tuesday's session, the stock fell 15.28% to approximately $0.254, down from a prior closing price of $0.2998. The pullback comes one day after the shares skyrocketed nearly 40% on the announcement of a partnership aimed at adding advanced volumetric imaging to the CyberKnife system — a sharp reversal that markets attribute primarily to profit-taking and a reassessment of the deal's near-term commercial impact.
Profit-Taking After a Samsung-Fueled Surge
The dominant catalyst for today's decline is the unwinding of Monday's explosive rally. On Saturday, ARAY announced a collaboration with Samsung HME America, operating as Samsung NeuroLogica, to pursue advanced volumetric imaging capabilities for its CyberKnife platform. The news, unveiled alongside the American Society for Radiation Oncology (ASTRO) Annual Meeting in Boston, sent the stock up approximately 39% on Monday, with intraday gains pushing shares as high as $0.382 on volume of more than 370 million shares — a dramatic departure from its roughly one-million-share daily average.
However, the partnership carries meaningful caveats. Accuray and Samsung NeuroLogica said the collaboration would progress through "phased development activities," and no commercial product has been announced. With future developments dependent on ongoing technical, clinical, and commercial evaluation and regulatory requirements, some traders moved to lock in gains from the rapid advance, driving the stock lower Tuesday morning.
Fundamental and Balance-Sheet Headwinds
Beneath the headline news, ARAY continues to face a difficult financial backdrop that makes sharp speculative moves prone to reversals. The company has reported declining revenue and persistent net losses, with negative operating margins and a trailing twelve-month loss per share of roughly $0.40. Its debt-to-equity ratio remains elevated, and earlier this year Accuray unveiled a $55 million recapitalization with its largest lender and shareholder, TCW, which included a debt-for-preferred-stock exchange and a planned reverse stock split intended to regain Nasdaq listing compliance after a prior delisting warning. These dilution and liquidity concerns resurfaced as the market looked beyond Monday's partnership enthusiasm.
Market Context and Trading Activity
The move reflects highly elevated volatility rather than a broad sector downturn. Monday's trading turnover of hundreds of millions of shares dwarfed ARAY's typical volume, and Tuesday's pullback occurred against a backdrop of extraordinary price swings — the stock's Monday range spanned more than 45% from trough to peak. Technical measures were stretched after the rally, leaving the shares vulnerable as momentum traders and short-term speculators exited. The decline is largely idiosyncratic to the stock, driven by the post-announcement re-pricing rather than a coordinated move across the medical-device or radiation-oncology peer group.
What Comes Next for ARAY
Looking ahead, investors will monitor whether ARAY can hold recent levels and whether the Samsung NeuroLogica collaboration translates into tangible development milestones. Key dates include the company's next earnings report, expected in early November, which will provide a clearer view of revenue trends and progress on its transformation plan. The status of the planned reverse stock split and any steps toward regaining Nasdaq compliance remain central risks, as does continued dilution from the recapitalization. With limited analyst coverage and a consensus view of "Hold," the stock is likely to remain volatile as it balances innovation-driven optimism against a challenged balance sheet.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are among the strongest performers under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each differing by strategy, timeframe, performance metrics, and the symbols they trade. Explore the Trending AI Robots to discover which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ARAY in upward trend: price rose above 50-day moving average on September 28, 2026
ARAY moved above its 50-day moving average on September 28, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARAY's RSI Oscillator exited the oversold zone, 34 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 69 cases where ARAY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on September 28, 2026. You may want to consider a long position or call options on ARAY as a result. In 76 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for ARAY just turned positive on September 28, 2026. Looking at past instances where ARAY's MACD turned positive, the stock continued to rise in 36 of 49 cases over the following month. The odds of a continued upward trend are 73%.
Following a +12.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARAY advanced for three days, in 156 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The 10-day moving average for ARAY crossed bearishly below the 50-day moving average on September 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
ARAY broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARAY entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. ARAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.859) is normal, around the industry mean (10.853). P/E Ratio (86.490) is within average values for comparable stocks, (98.910). Projected Growth (PEG Ratio) (2.060) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.070) is also within normal values, averaging (39.828).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical equipment
Industry MedicalNursingServices
Advertisement